Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 994-997

  Breccia, Massimo ^a   Latagliata, Roberto ^a   Carmosino, Ida ^a   Guarini, Anna ^a   Diverio, Daniela ^a   De Cuia, Rosaria ^a   Cimino, Giuseppe ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD135 ANTIGEN; CD15 ANTIGEN; CD34 ANTIGEN; FIBRINOGEN; FLT3 LIGAND; GENE PRODUCT; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN CAN; PROTEIN CBFBETA; PROTEIN DEK; PROTEIN MYH11; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; AGED; ANTIGEN EXPRESSION; BLAST CELL; BLAST CELL COUNT; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; DISEASE CLASSIFICATION; FAB CLASSIFICATION; FEMALE; FEVER; FIBRINOGEN BLOOD LEVEL; FUSION GENE; HIGH RISK PATIENT; HUMAN; KARYOTYPING; KIDNEY FAILURE; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; THROMBOPLASTIN TIME; TUMOR DIFFERENTIATION;

AGED; FMS-LIKE TYROSINE KINASE 3; GENE FREQUENCY; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROGNOSIS;

EID: 46749122665     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801947567     Document Type: Letter

References (12)

1. Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L. and Chen, I. M. (1997) Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, pp. 3323-3329.
2. Wahlin, A., Markevarn, B., Golovleva, I. and Nilsson, M. (2001) Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol, 115, pp. 25-33.
3. Abu-Duhier, F. M., Goodeve, A. C., Wilson, G. A., Gari, M. A., Peake, I. R. and Rees, D. C. (2000) FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol, 111, pp. 190-195.
4. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U. and Platzbecker, U. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, pp. 4326-4335.
5. Stirewalt, D. L., Kopecky, K. J., Meshinchi, S., Appelbaum, F. R., Slovak, M. L. and Willman, C. L. (2001) FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood, 97, pp. 3589-3595.
6. Andersson, A., Johansson, B., Lassen, C., Mitelman, F., Billstrom, R. and Fioretos, T. (2004) Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol, 72, pp. 307-313.
7. Beran, M., Luthra, R., Kantarjian, H. and Estey, E. (2004) FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res, 28, pp. 547-550.
8. Chomczynski, P. and Sacchi, N. (1987) Single step method of RNA isolation by acid guanidium thiocyanate - Phenol chloroform extraction. Anal Biochem, 162, pp. 156-159.
9. van Dongen, J. J., Macintyre, E. A., Gabert, J. A., Delabesse, E., Rossi, V. and Saglio, G. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia, 13, pp. 1901-1928.
10. Noguera, N. I., Breccia, M., Divona, M., Diverio, D., Costa, V. and De Santis, S. (2002) Alterations of the FLT3 gene in acute promyelocytic leukemia: Association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia, 16, pp. 2185-2189.
11. Munoz, L., Aventin, A., Villamor, N., Junca, J., Acebedo, G. and Domingo, A. (2003) Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica, 88, pp. 637-645.
12. Knapper, S., Burnett, A. K., Littlewood, T., Kell, W. J., Agrawal, S. and Chopra, R. (2006) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukaemia not considered fit for intensive chemotherapy. Blood, 108, pp. 3262-3270.